PMID- 37197570
OWN - NLM
STAT- MEDLINE
DCOM- 20230519
LR  - 20231119
IS  - 1466-1861 (Electronic)
IS  - 0962-9351 (Print)
IS  - 0962-9351 (Linking)
VI  - 2023
DP  - 2023
TI  - Evaluation of Intralymphatic Immunotherapy in Allergic Rhinitis Patients: A 
      Systematic Review and Meta-analysis.
PG  - 9377518
LID - 10.1155/2023/9377518 [doi]
LID - 9377518
AB  - BACKGROUND: Intralymphatic immunotherapy (ILIT) is short-course administration of 
      allergen-specific immunotherapy (AIT). This study is aimed at assessing the 
      clinical efficacy and safety of ILIT in patients with allergic rhinitis (AR). 
      METHODS: MEDLINE, PUBMED, and Cochrane Library were used to conduct electronic 
      searches for clinical trials comparing ILIT and placebo in patients with AR. The 
      final search took place on August 24, 2022. Cochrane Handbook for Systematic 
      Reviews of Interventions was used to assess the risk of bias in the included 
      studies. The outcomes included combined symptom and medication scores (CSMS), 
      visual analog scale (VAS), allergic rhinoconjunctivitis quality of life (RQLQ), 
      Skin-prick test (SPT), and adverse events (AEs). Data were synthesized as mean 
      difference (MD)/standard mean difference (SMD) or risk difference (RD) and 95% 
      confidence interval (CI). RESULTS: Thirteen studies (454 participants) were 
      included in this study. The ILIT group had better clinical improvement on the 
      CSMS (random effects model, SMD-0.85, 95% CI [-1.58, -0.11], P = 0.02) and RQLQ 
      (fixed-effects model, MD-0.42, 95% CI [0.69, 0.15], P = 0.003) than the placebo 
      group. The booster injection was beneficial for CSMS (P < 0.0001), and the 4-week 
      injection interval was superior to the 2-week injection period for improving VAS 
      (P < 0.0001). Local swelling or erythema was the main AE following injection 
      (random effects model, RD 0.16, 95% CI [0.05, 0.27], P = 0.005). Discussion. For 
      individuals with AR, ILIT is safe and effective. ILIT alleviates clinical 
      symptoms and reduces pharmaceutical consumption without causing severe AEs. 
      However, the validity of this study is compromised by the substantial 
      heterogeneity and risk of bias in the included researches. 
      RegistrationCRD42022355329.
CI  - Copyright (c) 2023 Sijie Jiang et al.
FAU - Jiang, Sijie
AU  - Jiang S
AD  - Department of Otolaryngology Head and Neck Surgery, Xiangya Hospital of Central 
      South University, Changsha, China.
AD  - Hunan Province Key Laboratory of Otolaryngology Critical Diseases, Xiangya 
      Hospital of Central South University, Changsha, China.
AD  - National Clinical Research Center for Geriatric Disorders, Xiangya Hospital of 
      Central South University, Changsha, China.
FAU - Xie, Shaobing
AU  - Xie S
AD  - Department of Otolaryngology Head and Neck Surgery, Xiangya Hospital of Central 
      South University, Changsha, China.
AD  - Hunan Province Key Laboratory of Otolaryngology Critical Diseases, Xiangya 
      Hospital of Central South University, Changsha, China.
AD  - National Clinical Research Center for Geriatric Disorders, Xiangya Hospital of 
      Central South University, Changsha, China.
FAU - Tang, Qingping
AU  - Tang Q
AD  - Department of Rehabilitation, Brain Hospital of Hunan Province, Hunan University 
      of Chinese Medicine, Changsha, China.
FAU - Zhang, Hua
AU  - Zhang H
AD  - Department of Otolaryngology Head and Neck Surgery, Xiangya Hospital of Central 
      South University, Changsha, China.
AD  - Hunan Province Key Laboratory of Otolaryngology Critical Diseases, Xiangya 
      Hospital of Central South University, Changsha, China.
AD  - National Clinical Research Center for Geriatric Disorders, Xiangya Hospital of 
      Central South University, Changsha, China.
FAU - Xie, Zhihai
AU  - Xie Z
AD  - Department of Otolaryngology Head and Neck Surgery, Xiangya Hospital of Central 
      South University, Changsha, China.
AD  - Hunan Province Key Laboratory of Otolaryngology Critical Diseases, Xiangya 
      Hospital of Central South University, Changsha, China.
AD  - National Clinical Research Center for Geriatric Disorders, Xiangya Hospital of 
      Central South University, Changsha, China.
FAU - Zhang, Junyi
AU  - Zhang J
AUID- ORCID: 0009-0001-6714-0142
AD  - Department of Otolaryngology Head and Neck Surgery, Xiangya Hospital of Central 
      South University, Changsha, China.
AD  - Hunan Province Key Laboratory of Otolaryngology Critical Diseases, Xiangya 
      Hospital of Central South University, Changsha, China.
AD  - National Clinical Research Center for Geriatric Disorders, Xiangya Hospital of 
      Central South University, Changsha, China.
FAU - Jiang, Weihong
AU  - Jiang W
AUID- ORCID: 0000-0002-3854-8923
AD  - Department of Otolaryngology Head and Neck Surgery, Xiangya Hospital of Central 
      South University, Changsha, China.
AD  - Hunan Province Key Laboratory of Otolaryngology Critical Diseases, Xiangya 
      Hospital of Central South University, Changsha, China.
AD  - National Clinical Research Center for Geriatric Disorders, Xiangya Hospital of 
      Central South University, Changsha, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20230508
PL  - United States
TA  - Mediators Inflamm
JT  - Mediators of inflammation
JID - 9209001
SB  - IM
MH  - Humans
MH  - *Quality of Life
MH  - *Rhinitis, Allergic/therapy
MH  - Desensitization, Immunologic
MH  - Treatment Outcome
PMC - PMC10185423
COIS- The authors have no conflicts of interest to declare.
EDAT- 2023/05/18 01:07
MHDA- 2023/05/19 06:42
PMCR- 2023/05/08
CRDT- 2023/05/17 20:03
PHST- 2022/09/22 00:00 [received]
PHST- 2022/11/22 00:00 [revised]
PHST- 2023/03/18 00:00 [accepted]
PHST- 2023/05/19 06:42 [medline]
PHST- 2023/05/18 01:07 [pubmed]
PHST- 2023/05/17 20:03 [entrez]
PHST- 2023/05/08 00:00 [pmc-release]
AID - 10.1155/2023/9377518 [doi]
PST - epublish
SO  - Mediators Inflamm. 2023 May 8;2023:9377518. doi: 10.1155/2023/9377518. 
      eCollection 2023.